









Markets
/
Stocks
/
nasdaq-tsha
/

Taysha Gene Therapies Inc

TSHA

2.990USD

+0.090+3.10%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

815.46MMarket Cap

LossP/E TTM



Taysha Gene Therapies Inc

2.990

+0.090+3.10%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

98 / 506

Overall Ranking

206 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

8.667

Target Price

+198.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 233.05% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 8.33M.

Undervalued

The company’s latest PE is -8.96, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 201.11M shares, decreasing 8.38% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 10.89M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-18

The company's current financial score is 6.46, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.99M, representing a year-over-year increase of 78.60%, while its net profit experienced a year-over-year increase of 28.45%.

Score

Industry at a Glance

Previous score

6.46

Change



Financials

8.99

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.27

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.19

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -8.69, which is -94.60% below the recent high of -0.47 and 51.16% above the recent low of -4.24.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 98/506

No Data

Earnings Forecast

Currency: USD Updated：2025-09-18

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Taysha Gene Therapies Inc is 8.00, with a high of 14.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Buy

Current Rating

8.667

Target Price

+198.85%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Taysha Gene Therapies Inc

TSHA

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-18

The company’s current price momentum score is 6.75, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 3.28 and the support level at 2.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.75

Change

0.19

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.073

Neutral

RSI(14)

50.473

Neutral

STOCH(KDJ)(9,3,3)

23.188

Neutral

ATR(14)

0.186

High Vlolatility

CCI(14)

-48.020

Neutral

Williams %R

66.667

Sell

TRIX(12,20)

0.381

Sell

StochRSI(14)

69.126

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

2.964

Buy

MA10

3.119

Sell

MA20

3.033

Sell

MA50

2.843

Buy

MA100

2.667

Buy

MA200

2.201

Buy

Institutional Confidence

Currency: USD Updated：2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 79.83%, representing a quarter-over-quarter decrease of 6.59%. The largest institutional shareholder is The Vanguard, holding a total of 10.89M shares, representing 3.99% of shares outstanding, with 8.11% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Manning (Paul B.)

25.60M

+3.02%

RTW Investments L.P.

18.79M

+116.63%

RA Capital Management, LP

10.87M

Avoro Capital Advisors LLC

20.00M

Fidelity Management & Research Company LLC

15.63M

-4.48%

Morgan Stanley & Co. LLC

14.64M

-5.27%

Octagon Capital Advisors LP

10.70M

+2.39%

BlackRock Institutional Trust Company, N.A.

12.44M

-0.73%

Invus Public Equities Advisors, LLC

6.51M

-1.33%

Risk Assessment

Currency: USD Updated：2025-09-18

The company’s current risk assessment score is 3.13, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.95. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.